A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age related Macular Degeneration

1. Men and women * 50 years of age at the Screening visit;, 2. Females must be
at least 1 year postmenopausal, or surgically sterilized, or, if of
childbearing potential, must have a negative pregnancy test at the Screening
visit;, o Women of childbearing potential must agree to use a highly effective
method of contraception throughout the study (See complete list in the Study
Procedures Manual);, 3. Have received no previous treatment for neovascular
AMD, including laser photocoagulation and/or photodynamic therapy (PDT) and/or
IVT VEGF antagonists (treatment naïve) and;, 4. Have active subfoveal CNV
lesions secondary to AMD (including polypoidal choroidal vasculopathy (PCV))
evidenced by subfoveal FA leakage, or definite subfoveal fluid by SD-OCT in the
study eye at Screening;, 5. Have CNV that is at least 50% of total lesion size
in the study eye at Screening;, 6. Have a ETDRS BCVA letter score of 78 to 25
(approximately 20/32 to 20/320 equivalent) in the study eye at Screening;, 7.
Have ocular media (lens, cornea, vitreous) of adequate clarity to permit high
quality fundus imaging;, 8. Are willing and able to sign the study written
informed consent form (ICF).

1. Have had any prior ocular or systemic treatment (investigational or
approved) or surgery for the treatment of neovascular AMD in the study eye
except dietary supplements or vitamins;
2. Have participated as a subject in any interventional clinical trial within
one month (30 days) prior to Baseline visit;
3. Have a total lesion size greater than twelve disc areas (30.5 mm2),
including blood, fibrosis and neovascularization, as assessed by FA in the
study eye at Screening;
4. Have a subretinal hemorrhage that is either 50% or more of the total lesion
area, or blood is under the fovea and is one or more disc areas in size
(greater than 2.5 mm2) in the study eye at Screening;
5. Have scarring or fibrosis making up greater than 50% of total lesion in the
study eye at Screening; and/or scarring, fibrosis or atrophy involving the
center of the fovea in the study eye at Screening;
6. Have any retinal pigment epithelial tears or rips in the study eye at
Screening or upon examination at Baseline;
7. Have any vitreous hemorrhage in the study eye upon examination at Baseline
or history of vitreous hemorrhage within eight weeks prior to Screening;
8. Have any other cause of CNV, including pathologic myopia (defined per
protocol as spherical equivalent of -8 diopters or more), ocular histoplasmosis
syndrome, angioid streaks, inherited macular dystrophies, choroidal rupture,
uveitis, punctate inner choroidopathy, or multifocal choroiditis in the study
eye at Screening;
9. Have a history of or clinical evidence of significant diabetic retinopathy
that could impact assessment of vision or affect central vision, diabetic
macular edema, or any other vascular disease other than AMD including history
or clinical evidence of retinal vein occlusion affecting the study eye at
Screening;
10. Have had prior pars plana vitrectomy in the study eye;
11. Have presence of a full thickness macular hole at Screening or upon
examination at Baseline or a history of a full thickness macular hole in the
study eye;
12. Have a history of intraocular or periocular surgery within three months of
Baseline in the study eye, except in the case of lid surgery, which may not
have taken place within one month of Baseline as long as it is unlikely to
interfere with IVT injection;
13. Have prior trabeculectomy or other filtration surgery in the study eye;
14. Have uncontrolled glaucoma (defined as intraocular pressure (IOP) greater
than or equal to 22 mmHg at Baseline despite treatment with more than two
anti-glaucoma medications) in the study eye;
15. Have active intraocular inflammation in either eye at Screening or upon
examination at Baseline or a history of uveitis in either eye;
16. Have active ocular or periocular infection in either eye, or a history of
any ocular or periocular infection within the two weeks prior to Screening in
either eye;
17. Have presence or history of scleromalacia in either eye;
18. Have aphakia or pseudophakia with absence of posterior capsule (unless it
occurred as a result of yttrium aluminum garnet (YAG) posterior capsulotomy) in
the study eye;
19. Have had previous therapeutic radiation in the region of the study eye;
20. Have history of corneal transplant or presence of a corneal dystrophy that
interferes with IOP measurements or imaging in the study eye;
21. Significant media opacities, including cataract, in the study eye that, in
the opinion of the Investigator, could require either medical or surgical
intervention during the study period;
22. Have any concurrent ocular condition in the study eye that, in the opinion
of the Investigator, could either increase the risk to the subject beyond what
is to be expected from standard procedures of intraocular injection, or that
otherwise may interfere with the injection procedure or with evaluation of
efficacy or safety during the study;
23. Have any evidence by medical history, physical examination or clinical
laboratory testing at Screening or Baseline that shows reasonable suspicion of
a disease or condition that contraindicates the use of study medication
(conbercept or aflibercept) or that might affect interpretation of the results
of the study or render the subject at high risk for treatment complications;
24. Have any use of long acting intraocular steroids, including implants,
within six months prior to Day 1, Baseline;
25. Have any known allergy to povidone iodine or known serious allergy to the
fluorescein sodium for injection in angiography;
26. Any history of known contraindications indicated in the Food and Drug
Administration (FDA)-approved label for the active control;
27. If female, be pregnant (positive urine pregnancy test at Screening) or
breastfeeding